Evolve Hypertension Practice Exam: Prep, Questions, and Study Guide

Nadolol is a non-selective beta-adrenergic blocker that can affect both beta-1 and beta-2 receptors. This means that it may lead to bronchoconstriction, particularly in patients with respiratory conditions such as asthma. In asthma, the bronchial passages are already sensitive and narrowing them further could potentially exacerbate respiratory symptoms and lead to asthma exacerbations. Therefore, initiating or continuing nadolol therapy in a patient with asthma would be questionable, as it poses a risk of worsening their condition and increasing the likelihood of severe respiratory complications.

In contrast, the other conditions listed do not present the same degree of concern regarding nadolol's effects. While careful monitoring may be warranted for patients with diabetes or chronic bronchitis, neither condition inherently contraindicates the use of a non-selective beta-blocker. For hypertension, nadolol is actually prescribed as a treatment option. Thus, the most significant reason to question the use of nadolol is its potential negative impact on a patient with asthma.